BR112013023914A2 - derivados de benzo [b] [1,4] oxazina como moduladores de receptor sensor de cálcio - Google Patents
derivados de benzo [b] [1,4] oxazina como moduladores de receptor sensor de cálcioInfo
- Publication number
- BR112013023914A2 BR112013023914A2 BR112013023914A BR112013023914A BR112013023914A2 BR 112013023914 A2 BR112013023914 A2 BR 112013023914A2 BR 112013023914 A BR112013023914 A BR 112013023914A BR 112013023914 A BR112013023914 A BR 112013023914A BR 112013023914 A2 BR112013023914 A2 BR 112013023914A2
- Authority
- BR
- Brazil
- Prior art keywords
- oxazine
- receptor modulators
- benzo derivatives
- calcium sensor
- sensor receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN367KO2011 | 2011-03-18 | ||
| PCT/IB2012/051268 WO2012127388A1 (en) | 2011-03-18 | 2012-03-16 | Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013023914A2 true BR112013023914A2 (pt) | 2016-12-13 |
Family
ID=54192843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013023914A BR112013023914A2 (pt) | 2011-03-18 | 2012-03-16 | derivados de benzo [b] [1,4] oxazina como moduladores de receptor sensor de cálcio |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9464063B2 (pt) |
| EP (1) | EP2686306B1 (pt) |
| JP (1) | JP6033835B2 (pt) |
| KR (1) | KR20140051846A (pt) |
| CN (1) | CN103459377B (pt) |
| AP (1) | AP2013007153A0 (pt) |
| AU (1) | AU2012232706B2 (pt) |
| BR (1) | BR112013023914A2 (pt) |
| CA (1) | CA2829466A1 (pt) |
| EA (1) | EA024893B9 (pt) |
| IL (1) | IL228461A0 (pt) |
| MX (1) | MX2013010670A (pt) |
| SG (1) | SG193331A1 (pt) |
| WO (2) | WO2012127385A1 (pt) |
| ZA (1) | ZA201306837B (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2817299T3 (da) * | 2012-02-24 | 2019-09-16 | Lupin Ltd | Substituerede chromanforbindelser som modulatorer af calciumdetekterende receptorer |
| WO2013136288A1 (en) | 2012-03-16 | 2013-09-19 | Lupin Limited | Substituted 3,4-dihydro-2h-benzo[b] [1,4]oxazine compounds as calcium sensing receptor modulators |
| WO2014033604A1 (en) | 2012-08-27 | 2014-03-06 | Lupin Limited | Arylalkylamine compounds as calcium sensing receptor modulators |
| TW201602062A (zh) | 2013-08-12 | 2016-01-16 | 魯賓有限公司 | 取代聯苯基化合物作為鈣敏感受體調節劑 |
| WO2015028938A1 (en) | 2013-08-28 | 2015-03-05 | Lupin Limited | Substituted naphthalene compounds as calcium sensing receptor modulators |
| JP6203954B2 (ja) | 2013-10-25 | 2017-09-27 | ノバルティス アーゲー | Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体 |
| WO2015162538A1 (en) | 2014-04-21 | 2015-10-29 | Lupin Limited | Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease |
| US20180185341A1 (en) | 2014-10-03 | 2018-07-05 | Novartis Ag | Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
| CN104464530B (zh) * | 2014-11-18 | 2017-08-25 | 深圳市华星光电技术有限公司 | 曲面型显示装置 |
| US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
| WO2017007755A1 (en) | 2015-07-06 | 2017-01-12 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| WO2017007756A1 (en) | 2015-07-06 | 2017-01-12 | Rodin Therapeutics, Inc | Hetero-halo inhibitors of histone deacetylase |
| WO2017037616A1 (en) | 2015-08-31 | 2017-03-09 | Lupin Limited | Arylalkylamine compounds as calcium sensing receptor modulators |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| EP3570834B1 (en) | 2017-01-11 | 2021-12-22 | Alkermes, Inc. | Bicyclic inhibitors of histone deacetylase |
| MA49839B1 (fr) | 2017-08-07 | 2022-05-31 | Alkermes Inc | Inhibiteurs bicycliques de la histone déacétylase |
| EP4081210A1 (en) * | 2019-12-27 | 2022-11-02 | Lupin Limited | Pharmaceutical composition of casr modulators and methods and uses thereof |
| JP2023512918A (ja) * | 2020-01-17 | 2023-03-30 | ルピン・リミテッド | クロマン化合物を調製するための方法、プロセスおよび中間体 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1109880A (zh) | 1994-02-03 | 1995-10-11 | 合成实验室公司 | 3-(2-氨基乙基)-4-[3-(三氟甲基)苯甲酰基]-3，4-二氢-2h-1，4-苯并噁嗪衍生物、制备及其应用 |
| FR2809396B1 (fr) * | 2000-05-24 | 2005-10-14 | Centre Nat Rech Scient | Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation |
| FR2812875B1 (fr) | 2000-08-08 | 2003-12-12 | Centre Nat Rech Scient | Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation |
| US6908935B2 (en) * | 2002-05-23 | 2005-06-21 | Amgen Inc. | Calcium receptor modulating agents |
| WO2004069793A2 (en) | 2003-01-28 | 2004-08-19 | Bristol-Myers Squibb Company | Novel 2-substituted cyclic amines as calcium sensing receptor modulators |
| JPWO2004106280A1 (ja) | 2003-05-28 | 2006-07-20 | 日本たばこ産業株式会社 | ＣａＳＲアンタゴニスト |
| WO2006122156A2 (en) * | 2005-05-09 | 2006-11-16 | Hydra Biosciences, Inc. | Compounds for modulating trpv3 function |
| JP4573133B2 (ja) * | 2005-05-19 | 2010-11-04 | アステラス製薬株式会社 | ピロリジン誘導体またはその塩 |
| AU2007303846B2 (en) | 2006-10-04 | 2011-03-10 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists |
| CA2672956C (en) * | 2006-10-26 | 2015-02-10 | Amgen Inc. | Calcium receptor modulating agents |
| US8153658B2 (en) * | 2006-11-16 | 2012-04-10 | Astellas Pharma, Inc. | Piperidine derivative or salt thereof |
| KR20100108348A (ko) | 2007-11-23 | 2010-10-06 | 레오 파마 에이/에스 | 질병 치료용의 신규한 사이클릭 탄화수소 화합물 |
| EP2345636B1 (en) | 2008-10-03 | 2016-03-30 | Ajinomoto Co., Inc. | Casr agonist |
| WO2010042642A1 (en) | 2008-10-08 | 2010-04-15 | Amgen Inc. | Calcium receptor modulating agents |
| WO2010090069A1 (ja) * | 2009-02-05 | 2010-08-12 | ヤンマー株式会社 | Ｅｇｒ装置及びこれを備えたエンジン装置 |
| US8765676B2 (en) | 2009-05-27 | 2014-07-01 | Leo Pharma A/S | Calcium sensing receptor modulating compounds and pharmaceutical use thereof |
| WO2010150837A1 (ja) | 2009-06-25 | 2010-12-29 | 第一三共株式会社 | インドリン誘導体 |
-
2012
- 2012-03-16 KR KR1020137026964A patent/KR20140051846A/ko not_active Application Discontinuation
- 2012-03-16 JP JP2014500512A patent/JP6033835B2/ja not_active Expired - Fee Related
- 2012-03-16 EA EA201370205A patent/EA024893B9/ru not_active IP Right Cessation
- 2012-03-16 CN CN201280013968.7A patent/CN103459377B/zh not_active Expired - Fee Related
- 2012-03-16 EP EP12713351.0A patent/EP2686306B1/en active Active
- 2012-03-16 MX MX2013010670A patent/MX2013010670A/es unknown
- 2012-03-16 SG SG2013067004A patent/SG193331A1/en unknown
- 2012-03-16 AU AU2012232706A patent/AU2012232706B2/en not_active Ceased
- 2012-03-16 WO PCT/IB2012/051263 patent/WO2012127385A1/en active Application Filing
- 2012-03-16 BR BR112013023914A patent/BR112013023914A2/pt active Search and Examination
- 2012-03-16 WO PCT/IB2012/051268 patent/WO2012127388A1/en active Application Filing
- 2012-03-16 US US14/005,944 patent/US9464063B2/en not_active Expired - Fee Related
- 2012-03-16 CA CA2829466A patent/CA2829466A1/en not_active Abandoned
- 2012-03-16 AP AP2013007153A patent/AP2013007153A0/xx unknown
-
2013
- 2013-09-11 ZA ZA2013/06837A patent/ZA201306837B/en unknown
- 2013-09-16 IL IL228461A patent/IL228461A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG193331A1 (en) | 2013-10-30 |
| CN103459377B (zh) | 2016-09-07 |
| JP2014510097A (ja) | 2014-04-24 |
| JP6033835B2 (ja) | 2016-11-30 |
| MX2013010670A (es) | 2013-12-06 |
| EA024893B1 (ru) | 2016-10-31 |
| EP2686306A1 (en) | 2014-01-22 |
| CN103459377A (zh) | 2013-12-18 |
| US9464063B2 (en) | 2016-10-11 |
| CA2829466A1 (en) | 2012-09-27 |
| KR20140051846A (ko) | 2014-05-02 |
| AU2012232706A1 (en) | 2013-09-26 |
| WO2012127385A1 (en) | 2012-09-27 |
| EP2686306B1 (en) | 2017-01-04 |
| EA024893B9 (ru) | 2017-01-30 |
| AU2012232706B2 (en) | 2016-12-15 |
| IL228461A0 (en) | 2013-12-31 |
| ZA201306837B (en) | 2015-05-27 |
| US20140018358A1 (en) | 2014-01-16 |
| AP2013007153A0 (en) | 2013-09-30 |
| WO2012127388A1 (en) | 2012-09-27 |
| NZ616676A (en) | 2015-09-25 |
| EA201370205A1 (ru) | 2014-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013023914A2 (pt) | derivados de benzo [b] [1,4] oxazina como moduladores de receptor sensor de cálcio | |
| BR112013002871A2 (pt) | derivados de isoxazolina como agentes antiparasitários | |
| BR112013023068A2 (pt) | derivados de isoxazolina espirocíclica como agentes antiparasíticos | |
| CU24152B1 (es) | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr | |
| BR112013015234A2 (pt) | derivados fosforosos como moduladores de receptor de quimiocina | |
| BR112012003704A2 (pt) | derivados de 3-amino-5-fenil-5,6-di-hidro-2h[1,4]oxazina | |
| BR112012028519A2 (pt) | compostos de 2,5,6,7-tetrahidro-[1,4]oxazepin-3-ilamina ou 2,3,6,7-tetrahidro-[1,4]oxazepin-5-ilamina | |
| HK1210472A1 (en) | Spirocyclic derivatives as antiparasitic agents | |
| BRPI1013766A2 (pt) | "derivados de isoxazol-piridina como moduladores de gaba" | |
| BRPI1008939A2 (pt) | 2-mercaptoquinolina-3-carboxamidas substituídas como moduladores de kncq2/3. | |
| BR112012018401A2 (pt) | sensor de posição rotativo | |
| CR20130403A (es) | Derivados de fluoro-piridinona útiles como agentes antibacterianos | |
| BRPI0910607A2 (pt) | derivados do ciclohexano espirocíclicos substituídos | |
| ZA201306576B (en) | Substituted morpholines as modulators for the calcium sensing receptor | |
| EP2887807A4 (en) | NOVEL DERIVATIVES OF BENZIMIDAZOLE HEXAHYDROFURO [3,2-B] FURANE | |
| BR112013021602A2 (pt) | derivados de heteroarila como moduladores de nachr alfa7. | |
| CU23870B1 (es) | Derivados de ciclopropilamida como moduladores h3 | |
| CO6890111A2 (es) | Derivados de isoxazolina como compuestos insecticidas | |
| BRPI1009200A2 (pt) | derivados de benzo tiadiazepinas como moduladores dos receptores ampa e nmda | |
| BRPI1009428A2 (pt) | 3-aminoisoxazolopiridina substituída como moduladores de kcnq2/3 | |
| HK1205117A1 (en) | Substituted chroman compounds as calcium sensing receptor modulators | |
| BRPI1008963A2 (pt) | 2-mercapto-3-aminopiridina substituída como moduladores de kcnq2/3 | |
| CO6811856A2 (es) | Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina | |
| BRPI1016115A8 (pt) | derivados de pirrolidina como antogonistas de receptador de nk3. | |
| CO6900142A2 (es) | Derivados de etinilo como moduladores del receptor metatrópico de glutamato |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25C | Requirement related to requested transfer of rights |
Owner name: LUPIN LIMITED (IN) |
|
| B25B | Requested transfer of rights rejected |
Owner name: LUPIN LIMITED (IN) |
|
| B25I | Requirement for requested change of headquarter |
Owner name: LUPIN LIMITED (IN) Free format text: A FIM DE ATENDER A ALTERACAO DE ENDERECO REQUERIDA ATRAVES DA PETICAO NO 870160061657 DE 21/10/2016, E NECESSARIO APRESENTAR DOCUMENTACAO PARA QUE O INTERESSADO SEJA O TITULAR DO PEDIDO. |
|
| B25H | Request for change of headquarter rejected |
Owner name: LUPIN LIMITED (IN) Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE SEDE CONTIDO NA PETICAO 87016061657 DE 21/10/2016,POR AUSENCIA DE CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI NO 2486, DE 28/08/2018. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2505 DE 08-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |